NDA 018642 · Cosette Pharms Nc
Beta-Val
Betamethasone Valerate · Topical
Last checked: Nov 19, 2026Latest source record: Nov 22, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1983
Mar 24, 1983
Approved uses
1
Original approval plus efficacy supplements
Registered trials
34
9 Phase 3, 2 recruiting
FAERS reports
4,589
4,066 serious, 240 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 20, 2024.
INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 24, 1983 Original approval
1 products under this application
- BETA-VAL · BETAMETHASONE VALERATE EQ 0.1% BASE · CREAM, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Betamethasone Valerate" as an intervention, any sponsor and status, largest first.
- Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)Pivotal-lookingRecruiting
McMaster UniversityAcademic, hospital or other
NCT05114096 · 3,254 participants (planned) · Start Jul 20, 2023 · Primary completion Dec 31, 2026
Drug: Celestone + placebo; Celestone + Celestone · For: Preterm Birth; Premature Birth; Complication of Prematurity and 2 more
Sites: Calgary, Canada; Edmonton, Canada; New Westminster, Canada · 25 sites in all
- Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01313221 · 310 participants · Start Apr 2011 · Primary completion Dec 2012
Drug: etanercept; Topical agents · For: Psoriasis
Sites: Calgary, Canada; Surrey, Canada; Vancouver, Canada · 24 sites in all
- Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive DermatosisPivotal-lookingStatus unknown
Mantecorp Industria Quimica e Farmaceutica Ltd.Industry
NCT01011621 · 170 participants (planned) · Start Feb 2010 · Primary completion Feb 2012
Drug: 0.5% prednisolone acetate cream; 0.1% betamethasone valerate cream · For: Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic and 1 more
- Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer PatientsPivotal-lookingCompleted
Cairo UniversityAcademic, hospital or other
NCT05285943 · 132 participants · Start Nov 4, 2021 · Primary completion Jan 31, 2024
Drug: Olive oil cream; Betamethasone Valerate Cream · For: Radiodermatitis; Acute
Sites: Cairo, Egypt
- New Topical Treatment in Plaque PsoriasisNot yet recruiting
Sohag UniversityAcademic, hospital or other
NCT07113756 · 70 participants (planned) · Start Sep 1, 2025 · Primary completion Dec 1, 2025
Drug: topical metformin 30% cream; betamethasone valerate.1% cream · For: Plaque Psoriasis
LEO PharmaIndustry
NCT03395132 · 68 participants · Start Jul 31, 2018 · Primary completion May 9, 2019
Drug: Fucicort® Lipid cream; Fucidin® cream and 2 more · For: Infected Atopic Dermatitis/Eczema
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 15 sites in all
- Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.Status unknown
Assiut UniversityAcademic, hospital or other
NCT06087796 · 60 participants (planned) · Start Oct 2023 · Primary completion Sep 2024
Drug: Betamethasone Valerate 0.1% Cream; Pentoxifylline and 1 more · For: Alopecia Areata
Sites: Asyut, Egypt
- New Topical Treatment in Patchy Alopecia AreataNot yet recruiting
Sohag UniversityAcademic, hospital or other
NCT07696585 · 60 participants (planned) · Start Jun 28, 2026 · Primary completion Sep 28, 2026
Drug: topical metformin 30% ointment; Topical Simvastatin 2% ointment and 1 more · For: Alopecia Areata
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,081
- macular degeneration644
- pain611
- off label use500
- pyrexia428
- malaise424
- nausea422
- headache416
- weight decreased416
- pruritus353
- rash338
- abdominal pain308
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 13 |
| 2005 | 13 |
| 2006 | 15 |
| 2007 | 17 |
| 2008 | 21 |
| 2009 | 25 |
| 2010 | 39 |
| 2011 | 56 |
| 2012 | 52 |
| 2013 | 85 |
| 2014 | 127 |
| 2015 | 179 |
| 2016 | 213 |
| 2017 | 189 |
| 2018 | 209 |
| 2019 | 340 |
| 2020 | 350 |
| 2021 | 569 |
| 2022 | 479 |
| 2023 | 499 |
| 2024 | 427 |
| 2025 | 388 |
| 2026 | 284 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- double-blind"double-bind.
Björnberg A, Hellgren L · Curr Med Res Opin 1975 · Clinical Trial, Comparative Study
- Seborrhoeic dermatitis.
Naldi L · BMJ Clin Evid 2010 · Systematic Review
- Seborrhoeic dermatitis.
Manríquez JJ, Uribe P · BMJ Clin Evid 2007 · Systematic Review
- Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis.
Kowalzick L · Br J Dermatol 2001 · Clinical Trial, Comparative Study
- Modified Delphi Consensus on Interventions for Acute Radiation Dermatitis in Breast Cancer: A Canadian Expert Perspective.
Cao JQ, Yassa M, Bolivar CHA, et al. · Int J Radiat Oncol Biol Phys 2025 · Consensus Statement, Systematic Review
- Interventions to reduce Staphylococcus aureus in the management of atopic eczema.
Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, et al. · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
Sponsor: Cosette Pharms Nc
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.